Allergy UK Statement on Palforzia

The manufacturer of Palforzia has informed healthcare providers that it will be discontinuing production worldwide. As a patient charity, we wanted to share this information with our community in case this affects you or your child.

Palforzia is indicated as a peanut immunotherapy (desensitisation treatment) for children with a peanut allergy. The manufacturer has advised that no new patients should be started on Palforzia after 1 April 2026. This decision is not related to the safety, quality or effectiveness of the treatment, but is due to strategic and operational considerations at Stallergenes, the manufacturer.

At present, there are no other licensed immunotherapy treatment options for peanut allergy. Without immunotherapy, children who have been diagnosed with a peanut allergy will need to continue strict peanut avoidance and continue to always carry their emergency medication and allergy action plan.

The manufacturer has reassured healthcare providers that there should be sufficient supplies of Palforzia for children who are already on treatment to complete their course. These children should continue taking their current dose of Palforzia and follow the advice given by their healthcare professional at their most recent appointment.

We understand that this news will be disappointing and upsetting for many families. As you know, Allergy UK remains committed to supporting our community and ensuring that the needs of people living with allergy are prioritised. There are a number of ongoing research trials into treatments for peanut allergy that are showing great promise, and we remain hopeful that new options will become available in the future.